These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Interim PET After Two ABVD Cycles in Early-Stage Hodgkin Lymphoma: Outcomes Following the Continuation of Chemotherapy Plus Radiotherapy. Simontacchi G; Filippi AR; Ciammella P; Buglione M; Saieva C; Magrini SM; Livi L; Iotti C; Botto B; Vaggelli L; Re A; Merli F; Ricardi U Int J Radiat Oncol Biol Phys; 2015 Aug; 92(5):1077-1083. PubMed ID: 26031367 [TBL] [Abstract][Full Text] [Related]
4. Post-ABVD/pre-radiotherapy (18)F-FDG-PET provides additional prognostic information for early-stage Hodgkin lymphoma: a retrospective analysis on 165 patients. Ciammella P; Filippi AR; Simontacchi G; Buglione M; Botto B; Mangoni M; Iotti C; Merli F; Marcheselli L; Bisi G; Ricardi U; Versari A Br J Radiol; 2016; 89(1061):20150983. PubMed ID: 27022777 [TBL] [Abstract][Full Text] [Related]
5. Combination chemoradiotherapy in early Hodgkin lymphoma. André MP Hematol Oncol Clin North Am; 2014 Feb; 28(1):33-47. PubMed ID: 24287066 [TBL] [Abstract][Full Text] [Related]
6. Interim PET After Two ABVD Cycles in Early-Stage Hodgkin Lymphoma: Outcomes Following the Continuation of Chemotherapy Plus Radiotherapy. In Reply to Adams and Kwee. Simontacchi G; Filippi AR; Ciammella P; Ricardi U Int J Radiat Oncol Biol Phys; 2015 Nov; 93(3):725-6. PubMed ID: 26461018 [No Abstract] [Full Text] [Related]
7. Interim PET After Two ABVD Cycles in Early-Stage Hodgkin Lymphoma: Outcomes Following the Continuation of Chemotherapy Plus Radiotherapy. In Regard to Simontacchi et al. Adams HJ; Kwee TC Int J Radiat Oncol Biol Phys; 2015 Nov; 93(3):724-5. PubMed ID: 26461017 [No Abstract] [Full Text] [Related]
8. Randomized comparison of consolidation radiation versus observation in bulky Hodgkin's lymphoma with post-chemotherapy negative positron emission tomography scans. Picardi M; De Renzo A; Pane F; Nicolai E; Pacelli R; Salvatore M; Rotoli B Leuk Lymphoma; 2007 Sep; 48(9):1721-7. PubMed ID: 17786707 [TBL] [Abstract][Full Text] [Related]
9. [Role of FDG-PET in Staging and Therapy of Children with Hodgkin Lymphoma]. Kluge R; Körholz D Klin Padiatr; 2011 Nov; 223(6):315-9. PubMed ID: 22012607 [TBL] [Abstract][Full Text] [Related]
10. The role of PET in Hodgkin's lymphoma and its impact on radiation oncology. Kobe C; Dietlein M; Kriz J; Furth C; Fuchs M; Borchmann P; Engert A; Eich HT Expert Rev Anticancer Ther; 2010 Sep; 10(9):1419-28. PubMed ID: 20836677 [TBL] [Abstract][Full Text] [Related]
11. FDG-PET response-adapted therapy: is 18F-fluorodeoxyglucose positron emission tomography a safe predictor for a change of therapy? Hutchings M Hematol Oncol Clin North Am; 2014 Feb; 28(1):87-103. PubMed ID: 24287070 [TBL] [Abstract][Full Text] [Related]
12. Assessment of tumor size reduction improves outcome prediction of positron emission tomography/computed tomography after chemotherapy in advanced-stage Hodgkin lymphoma. Kobe C; Kuhnert G; Kahraman D; Haverkamp H; Eich HT; Franke M; Persigehl T; Klutmann S; Amthauer H; Bockisch A; Kluge R; Wolf HH; Maintz D; Fuchs M; Borchmann P; Diehl V; Drzezga A; Engert A; Dietlein M J Clin Oncol; 2014 Jun; 32(17):1776-81. PubMed ID: 24799482 [TBL] [Abstract][Full Text] [Related]
13. Change of initial staging at early remission evaluation with FDG-PET/CT in Hodgkin lymphoma: a report of two cases. Molin D; Hagberg H; Suurküla M; Aström G Acta Oncol; 2010 May; 49(4):526-8. PubMed ID: 20397779 [No Abstract] [Full Text] [Related]
14. Assessment of Lymphoma Therapy Using (18)F-FDG PET. Lowe VJ; Wiseman GA J Nucl Med; 2002 Aug; 43(8):1028-30. PubMed ID: 12163627 [No Abstract] [Full Text] [Related]
15. 18-Fluorodeoxyglucose positron emission tomography/computed tomography for assessment of response to brentuximab vedotin treatment in relapsed and refractory Hodgkin lymphoma. Kahraman D; Theurich S; Rothe A; Kuhnert G; Sasse S; Scheid C; Dietlein M; Drzezga A; von Bergwelt-Baildon M; Kobe C Leuk Lymphoma; 2014 Apr; 55(4):811-6. PubMed ID: 23805904 [TBL] [Abstract][Full Text] [Related]
16. Role of FDG-PET in the implementation of involved-node radiation therapy for Hodgkin lymphoma patients. Girinsky T; Aupérin A; Ribrag V; Elleuch M; Fermé C; Bonniaud G; Ruelle C; Alberini JL; Celebic A; Edeline V Int J Radiat Oncol Biol Phys; 2014 Aug; 89(5):1047-1052. PubMed ID: 25035208 [TBL] [Abstract][Full Text] [Related]
17. Omitting radiotherapy in early positron emission tomography-negative stage I/II Hodgkin lymphoma is associated with an increased risk of early relapse: Clinical results of the preplanned interim analysis of the randomized EORTC/LYSA/FIL H10 trial. Raemaekers JM; André MP; Federico M; Girinsky T; Oumedaly R; Brusamolino E; Brice P; Fermé C; van der Maazen R; Gotti M; Bouabdallah R; Sebban CJ; Lievens Y; Re A; Stamatoullas A; Morschhauser F; Lugtenburg PJ; Abruzzese E; Olivier P; Casasnovas RO; van Imhoff G; Raveloarivahy T; Bellei M; van der Borght T; Bardet S; Versari A; Hutchings M; Meignan M; Fortpied C J Clin Oncol; 2014 Apr; 32(12):1188-94. PubMed ID: 24637998 [TBL] [Abstract][Full Text] [Related]
18. [18F]fluorodeoxyglucose positron emission tomography in the management of lymphomas. Kostakoglu L Clin Lymphoma Myeloma; 2008 Oct; 8(5):273-6. PubMed ID: 18854280 [No Abstract] [Full Text] [Related]